- Mithra grants license to Zentiva for commercialization of its vaginal contraceptive ring in three key European markets
- Consolidation of commercial roll-out in Europe with 17 countries already under license
- Production ongoing at Mithra CDMO for upcoming European commercial launches
Liege, Belgium, 06 July 2020 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it has entered into a license and supply agreement (LSA) with Zentiva for the commercialization of its hormonal contraceptive ring Myring™ in France, Poland and the United Kingdom. Based in Czech Republic, Zentiva is a pharmaceutical company with more than 4,700 people and a network of production sites – including flagship sites in Prague, Bucharest, and Ankleshwar.